The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score: A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy
Abstract
Oral anticoagulation (OAC) to prevent stroke has to be balanced against the potential harm of serious bleeding, especially intracranial haemorrhage (ICH). We determined the net clinical benefit (NCB) balancing effectiveness and safety of no antithrombotic therapy, aspirin and warfarin in AF patients with none or one stroke risk factor. Using Danish registries, we determined NCB using various definitions intrinsic to our cohort (Danish weights at 1 and 5 year follow-up), with risk weights which were derived from the hazard ratio (HR) of death following an event, relative to HR of death after ischaemic stroke. When aspirin was compared to no treatment, NCB was neutral or negative for both risk strata. For warfarin vs no treatment, NCB using Danish weights was neutral where no risk factors were present and using five years follow-up. For one stroke risk factor, NCB was positive for warfarin vs no treatment, for one year and five year follow-up. For warfarin vs aspirin use in patients with no risk factors, NCB was positive with one year follow-up, but neutral with five year follow-up. With one risk factor, NCB was generally positive for warfarin vs aspirin. In conclusion, we show a positive overall advantage (i.e. positive NCB) of effective stroke prevention with OAC, compared to no therapy or aspirin with one additional stroke risk factor, using Danish weights. 'Low risk' AF patients with no additional stroke risk factors (i.e.CHA2DS2-VASc 0 in males, 1 in females) do not derive…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rates of stroke and thromboembolism vary considerably in patients with CHA 2 DS 2 -VASc scores of 1 or 2 due to differences in outcomes, populations, and anticoagulation status (Web Addenda Table 1).371,376,377,1041”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [377]
Citations
Cites
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793 · cited 2×
“Importantly, we should not forget that OAC also reduces all cause mortality in AF patients, compared to placebo/control (1).”
Background2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,823
Self-citation2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,929
Self-citationEvaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation
Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., & Kirchhof, P. F. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.11.003 · Cited by 687
Self-citationThe Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
Singer, D. E., Chang, Y., Fang, M. C., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., & Go, A. S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00003 · Cited by 655
Research works printed but not linked: 2
- 10.1161/CIRCULATIONAHA.111.055079 · DOI · Paper page
- 10.1160/TH11-05-0364 · DOI · Paper page
Cited by
Sorted by citations
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
“– 375 The rates of stroke and thrombo-embolism vary considerably in patients with CHA2DS2VASc scores of 1 or 2 due to differences in outcomes, populations, and anticoagulation status (Web Table 1).(371,376,377,1041) We therefore commissioned an analysis of stroke risk in men and women”
Self-citationCollet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Self-citationStroke prevention in atrial fibrillation
Freedman, B., Potpara, T., & Lip, G. Y. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31257-0 · Cited by 484
Self-citationStroke prevention in atrial fibrillation: Past, present and future
Lip, G. Y. H., Freedman, B., Caterina, R. D., & Potpara, T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-11-0876 · Cited by 400
“Notwithstanding the fact that even one stroke risk factor confers an excess risk of stroke and death, and that OAC has a positive NCB with one or more stroke risk factors (25), the CHA2DS2-VASc score should be used in a stepwise approach to initially identify ‘low risk’ patients (Step 1), defined as a CHA2DS2-VASc sco…”
Self-citationChung, M. K., Refaat, M. M., Shen, W.-K., Kutyifa, V., Cha, Y., Biase, L. D., Baranchuk, A. M., Lampert, R., Natale, A., Fisher, J. D., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.025 · Cited by 261
Görenek, B., Bax, J. J., Boriani, G., Chen, S., Dagres, N., Glotzer, T. V., Healey, J. S., Israel, C. W., Kudaiberdieva, G., Levin, L., et al. (2017) · EP Europace · doi:10.1093/europace/eux163 · Cited by 249
“OAC refers to a NOAC or well controlled VKA, with time in the therapeutic range (TTR) >70%, given that the net clinical benefit for treatment is evident even with one stroke risk factor.(105) Most guidelines give a preference for the NOACs over VKA, given the efficacy, safety and convenience of the latter(1,106) as ev…”
Self-citationLip, G. Y. H., Fauchier, L., Freedman, S. B., Gelder, I. C. V., Natale, A., Gianni, C., Nattel, S., Potpara, T., Rienstra, M., Tse, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.16 · Cited by 248
Self-citation2020 Clinical guidelines for Atrial fibrillation and atrial flutter
Arakelyan, M. S., Bockeria, L. A., Vasilieva, E., Sp, G., Golukhova, E. Z., Gorev, M. V., Davtyan, K. V., Drapkina, O. M., Станиславовна, К. Е., Kuchinskaya, Е. А., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4594 · Cited by 258
Oral Anticoagulation in Very Elderly Patients With Atrial Fibrillation
Chao, T., Liu, C., Lin, Y., Chang, S., Lo, L., Hu, Y., Tuan, T., Liao, J., Chung, F., Chen, T., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031658 · Cited by 223
Self-citationLip, G. Y. H., Coca, A., Kahan, T., Boriani, G., Manolis, A. S., Olsen, M. H., Oto, A., Potpara, T., Steffel, J., Marín, F. R., et al. (2017) · EP Europace · doi:10.1093/europace/eux091 · Cited by 233
Self-citationComorbidity of atrial fibrillation and heart failure
Ling, L., Kistler, P. M., Kalman, J. M., SCHILLING, R. J., & Hunter, R. J. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.191 · Cited by 217
Lip, G. Y. H., & Lane, D. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13386 · Cited by 117
Self-citationKuo, L., Chao, T., Liu, C., Lin, Y., Chang, S., Lo, L., Hu, Y., Tuan, T., Liao, J., Chung, F., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005307 · Cited by 116
“Analysis of Net Clinical Benefit The NCB for the use of warfarin or antiplatelet therapy compared with no treatment was calculated using the formula: ðIschemic stroke rateno treatment Ischemic stroke rateanti thrombotic therapiesÞ weighting factor ðICH rateanti thrombotic therapies ICH rateno treatementÞ The weighting…”
InfluentialSelf-citationStroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy
Calenda, B. W., Fuster, V., Halperin, J. L., & Granger, C. B. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.106 · Cited by 117
Yoon, M., Yang, P., Jang, E., Yu, H. J., Kim, T., Uhm, J., Kim, J., Pak, H., Lee, M., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651482 · Cited by 113
Self-citationPerformance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation
Oldgren, J., Hijazi, Z., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Granger, C. B., Hylek, E. M., Lópes, R. D., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.022802 · Cited by 107
Chao, T., Lip, G. Y. H., Liu, C., Tuan, T., Chen, S., Wang, K.-L., Lin, Y., Chang, S., Lo, L., Hu, Y., et al. (2016) · Stroke · doi:10.1161/strokeaha.116.013880 · Cited by 106
Self-citationKim, T., Yang, P., Uhm, J., Kim, J., Pak, H., Lee, M., Joung, B., & Lip, G. Y. H. (2017) · Stroke · doi:10.1161/strokeaha.117.016926 · Cited by 104
“Several studies have demonstrated that the net clinical benefit of OAC is evident in AF patients with one or more stroke risk factors.(23,24) Various guidelines recommend OAC use based on the patients’ risk of stroke by the CHA 2 DS 2 -VASc score.”
Self-citationNielsen, P. B., Larsen, T. B., Skjøth, F., Overvad, T. F., & Lip, G. Y. H. (2016) · Scientific Reports · doi:10.1038/srep27410 · Cited by 102
Self-citationLee, S., Choi, E., Han, K., Cha, M., Oh, S., & Lip, G. Y. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189495 · Cited by 81
Self-citationGiugliano, R. P., Ruff, C. T., Wiviott, S. D., Nordio, F., Murphy, S. A., Kappelhof, J. A. N., Shi, M., Mercuri, M. F., Antman, E. M., & Braunwald, E. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.02.028 · Cited by 75
Görenek, B., Halvorsen, S., Kudaiberdieva, G., Bueno, H., Gelder, I. C. V., Lettino, M., Marín, F. R., Masip, J., Mueller, C. E., Okutucu, S., et al. (2020) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872619894255 · Cited by 70
Self-citationRegistries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice
Mazurek, M., Huisman, M. V., & Lip, G. Y. H. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.09.012 · Cited by 46
Self-citationProietti, M., Mujović, N. M., & Potpara, T. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1676074 · Cited by 45
Tu, S. J., Hanna‐Rivero, N., Elliott, A. D., Clarke, N., Huang, S., Pitman, B. M., Gallagher, C., Linz, D., Mahajan, R., Lau, D. H., et al. (2021) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14898 · Cited by 42
“of OAC in AF even in the setting of high bleeding risk, in part due to the overlap in both stroke and bleeding risk factors.(31,32) Several biological and clinical explanations have been postulated for the bleeding risk that anemia poses in AF.”
BackgroundLip, G. Y. H., & Nielsen, P. B. (2016) · Circulation · doi:10.1161/circulationaha.115.016713 · Cited by 40
Self-citation2025 Clinical practice guidelines for Atrial fibrillation and flutter
Golukhova, E. Z., Sp, G., Михайлов, Е. Н., Revishvili, A. S. H., Arakelyan, M. G., Vasilyeva, E. Y., Davtyan, K. V., Drapkina, O. M., Drozdova, L. Y., Станиславовна, К. Е., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6668 · Cited by 44
Overvad, T. F., Nielsen, P. B., & Lip, G. Y. H. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw022 · Cited by 37
Self-citationShin, S. Y., Han, S. J., Kim, J. S., Im, S. I., Shim, J., Ahn, J., Lee, E. M., Park, Y. M., Kim, J. H., Lip, G. Y. H., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012697 · Cited by 36
“19,20 Nevertheless, AF patients with 1 nongender CHA2DS2-VASc risk factor still have an elevated risk of stroke compared with patients with a CHA2DS2-VASc score of 0 and the clinical benefit of OAC may be positive in these patients.(5,7) However, the risk contribution of each component of the CHA2DS2-VASc score is not…”
BackgroundSelf-citationUpdated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019
Moreira, A. A. C. D. M., Costa, E. F. D. A., Miranda, R. D., Wajngarten, M., Galera, S. C., Filho, A. C. D. A., Toledo, M. A. D. V., Alves, J. D. C., Moriguchi, E. H., Rodrigues, N. L., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190086 · Cited by 39
Fauchier, L., Clémenty, N., Bisson, A., Stamboul, K., Ivanés, F., Angoulvant, D., Babuty, D., & Lip, G. Y. H. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1040-7 · Cited by 31
“Strokes associated with AF are more likely to be fatal and disabling, and even one stroke risk factor confers a significant risk and anticoagulation confers a positive net clinical benefit [21].”
BackgroundSelf-citationStroke Prevention in Atrial Fibrillation: Focus on Latin America
Massaro, A. R., & Lip, G. Y. H. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160116 · Cited by 30
Self-citationStroke prevention in atrial fibrillation
Lip, G. Y. H., Gue, Y. X., Zhang, J., Chao, T., Calkins, H. G., & Potpara, T. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.10.001 · Cited by 32
Self-citationLip, G. Y. H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv431 · Cited by 29
Self-citationCollet, J., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J. K., Bhatt, D. L., Dendale, P., Dorobanţu, M., Edvardsen, T., Folliguet, T. A., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.12.024 · Cited by 38
The ageing population is neglected in research studies of traumatic brain injury
Gaastra, B., Longworth, A., MATTA, B. F., Snelson, C., Whitehouse, T., Murphy, N., & Veenith, T. (2016) · British Journal of Neurosurgery · doi:10.3109/02688697.2015.1119240 · Cited by 27
Chao, T., Chan, Y., Chiang, C., Tuan, T., Liao, J., Chen, T., Lip, G. Y. H., & Chen, S. (2021) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcab076 · Cited by 26
Self-citationCarlos Jerjes-Sánchez, D., Corbalan, R. L., Barretto, A. C. P., Luciardi, H. L., Allu, J., Illingworth, L., Pieper, K. S., Kayani, G., & for the GARFIELD‐AF Investigators (2019) · Clinical Cardiology · doi:10.1002/clc.23176 · Cited by 25
“It has been suggested that in patients with a TTR <65%, the use of NOACs is likely to provide significant clinical benefits.(29) Indeed, the use of NOACs in AF patients would eliminate the requirement for frequent monitoring, which may limit the use of AC therapy in many regions of Latin America.”
BackgroundProietti, M., & Lip, G. Y. H. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.03.024 · Cited by 24
Self-citationOral Anticoagulants in the Oldest Old with Recent Stroke and Atrial Fibrillation
Polymeris, A. A., Macha, K., Paciaroni, M., Wilson, D., Koga, M., Cappellari, M., Schaedelin, S. A., Zietz, A., Peters, N., Seiffge, D. J., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26267 · Cited by 24
Self-citationDan, G., Iliodromitis, K. E., Scherr, D., Marín, F. R., Lenarczyk, R., Estner, H., Kostkiewicz, M., Dagres, N., & Lip, G. Y. H. (2018) · EP Europace · doi:10.1093/europace/euy094 · Cited by 23
Self-citationStroke prevention in atrial fibrillation: State of the art
Li, Y., & Lip, G. Y. H. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.09.057 · Cited by 21
“A recent study from an Asian population, including 11,046 AF patients >90 years, showed that warfarin was associated with a lower risk of ischemic stroke and positive NCB[94].”
BackgroundInfluentialSelf-citationLip, G. Y. H., Potpara, T., Boriani, G., & Blomström‐Lundqvist, C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12468 · Cited by 19
Self-citationAtrial Fibrillation in Patients With Hypertension
Lip, G. Y. H. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07901 · Cited by 19
“Even a single stroke risk factor confers risks of stroke and mortality, and oral anticoagulation confers a positive net clinical benefit compared with aspirin or no antithrombotic treatment.(8,9) Effective stroke prevention in AF means oral anticoagulation, whether as a vitamin K antagonist (eg, warfarin) or a non–vit…”
Self-citationStroke Prevention in Atrial Fibrillation
Voukalis, C., Shantsila, E., & Lip, G. Y. H. (2017) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2017.105 · Cited by 18
Self-citationEmerging Tools for Stroke Prevention in Atrial Fibrillation
Voukalis, C., Lip, G. Y. H., & Shantsila, E. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.01.017 · Cited by 16
“Whilst there are variousways to defineNCB, it ismost commonly estimatedbybalancing the risk of ischemic stroke without OAC against the risk of intracranial haemorrhage with OAC (Lip et al., 2015).”
BackgroundSelf-citationPotpara, T., Dagres, N., Mujović, N. M., Vasić, D., Ašanin, M., Nedeljkovic, M. A., Marín, F. R., Fauchier, L., Blomström‐Lundqvist, C., & Lip, G. Y. H. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0458-7 · Cited by 16
Self-citationDecision-making interventions to stop the global atrial fibrillation-related stroke tsunami
Cerasuolo, J. O., Montero‐Odasso, M., Ibáñez, A. M., Doocy, S., Lip, G. Y. H., & Sposato, L. A. (2017) · International Journal of Stroke · doi:10.1177/1747493016687579 · Cited by 17
“Contrarily, the net clinical benefit for aspirin is neutral.(18) Therefore, concordant with current guidelines, OACs are the treatment of choice for preventing ischemic stroke in high-risk AF patients (defined as having a CHA2DS2-VASc score of 2(19)) and in a considerable proportion with a single stroke risk factor (C…”
BackgroundSelf-citationEditors’ Choice 2016 papers in Thrombosis and Haemostasis
Lip, G. Y. H., & Weber, C. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-11-0899 · Cited by 14
“The journal also contributed to the debate on appropriate use of stroke risk scores, such as the CHA2DS2-VASc score – and whether OAC should be used in AF patients with bioprosthesis (23) or those with only one stroke risk factor, given the clearly positive net clinical benefit of OAC in such patients compared to aspi…”
Self-citationAdding Rigor to Stroke Rate Investigations in Patients With Atrial Fibrillation
Nielsen, P. B., & Lip, G. Y. H. (2017) · Circulation · doi:10.1161/circulationaha.116.025944 · Cited by 14
Self-citationRisk Stratification Models in Atrial Fibrillation
Shahid, F., & Lip, G. Y. H. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1597285 · Cited by 13
Self-citationYeh, Y., Chan, Y., Chen, S., Chang, S., Wang, C., Kuo, C.-T., Lip, G. Y. H., Chen, S., & Chao, T. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.03.011 · Cited by 12
Self-citationTsai, C.-T., Chan, Y., Liao, J., Chen, T., Lip, G. Y. H., Chen, S.-A., & Chao, T. (2024) · BMC Medicine · doi:10.1186/s12916-024-03338-7 · Cited by 11
“The NCB with 95% confidence intervals (CI) were calculated from rate differences of ischemic stroke and ICH of the present study based on the weights previously produced and reported in the studies by Singer et al. [20], Connolly et al. [21], and Lip et al. [22].”
Self-citationLee, J., Joung, B., Cha, M., Lee, J. H., Lim, W., Kim, T., Shin, S. Y., Uhm, J., Lim, H. E., Kim, J., et al. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.87.e1 · Cited by 11
State of play and future direction with NOACs: An expert consensus
Cohen, A. T., Lip, G. Y. H., Caterina, R. D., Heidbüchel, H., Zamorano, J. L., Agnelli, G., Verheugt, F. W. A., & Camm, A. J. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.04.001 · Cited by 10
Self-citationTiili, P., Jukka Putaala, A., Mehtälä, J., Khanfir, H., Niiranen, J., Korhonen, P. A., Raatikainen, P. M. J., & Lehto, M. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-0975 · Cited by 10
Shahid, F., Shantsila, E., & Lip, G. Y. H. (2016) · F1000Research · doi:10.12688/f1000research.10176.1 · Cited by 10
“In essence, patients with risk factors should be offered OAC unless contraindicated, given the positive net clinical benefit for treating such patients 6,10,11 .”
BackgroundInfluentialSelf-citationLee, J., Joung, B., Cha, M., Lee, J. H., Lim, W., Kim, T., Shin, S. Y., Uhm, J., Lim, H. E., Kim, J., et al. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.87 · Cited by 8
“하지만 연구마다 대상 환자군 과 항응고 치료 상태, 임상적 결과가 달리 설정되어 있어 상 당한 차이를 보이고 있어 신중한 해석이 필요하다[10,15-17].”
How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring
Lip, G. Y. H. (2016) · Circulation · doi:10.1161/circulationaha.115.016797 · Cited by 7
“European Society of Cardiology (ESC) guideline recommendations.(21)”
Self-citationEscalas de evaluación del riesgo tromboembólico y hemorrágico en la fibrilación auricular
Copete, J. P., Esteve‐Pastor, M. A., Roldán, V., Valdés, M., & Marín, F. R. (2016) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(16)30011-5 · Cited by 7
Potpara, T., Lip, G. Y. H., Blomström‐Lundqvist, C., Chiang, C., & Camm, A. J. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.02.026 · Cited by 6
Self-citationFibrilación auricular: enfoque para el médico no cardiólogo
de Caldas, U., Forero, J., Moreno, J., del Bosque, U., Agudelo, C. A., Cayre, I. P. S., Rodríguez, E., de Manizales, I. D. C., & Sánchez, P. (2017) · IATREIA · doi:10.17533/udea.iatreia.v30n4a05 · Cited by 7
“, reportaron recientemente que solo el 5% de los pacientes con FA que consultaban a urgencias tenían INR en rango terapéutico (15), lo cual está en consonancia con la baja tasa de tiempo en rango terapéutico que se ha demostrado en pacientes participantes de estudios clínicos controlados (66% del tiempo en rango terap…”
BackgroundInfluentialSkjøth, F., & Nielsen, P. B. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-07-0523 · Cited by 6
Self-citationNet Benefit of Early Anticoagulation for Stroke With Atrial Fibrillation
Polymeris, A. A., Branca, M., Sylaja, P. N., Sandset, E. C., de Sousa, D. A., Thomalla, G., Paciaroni, M., Gattringer, T., Strbian, D., Trelle, S., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.56307 · Cited by 5
Direct oral anticoagulant reversal: how, when and issues faced
Dzeshka, M. S., Pastori, D., & Lip, G. Y. H. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1379896 · Cited by 5
“The evidence, which supports initiation of OAC for prevention of stroke/systemic embolism in the presence of one or more additional CHA2DS2VASc stroke risk factors, is based on positive net clinical benefit of antithrombotic therapy against potential harm of serious bleeding [43,44].”
BackgroundSelf-citationJung, M., Byeon, K., Kang, K., Lee, W. S., Kim, S., Park, Y. M., Hwang, Y. M., Lee, S. H., Jin, E., Roh, S., et al. (2023) · Journal of Arrhythmia · doi:10.1002/joa3.12840 · Cited by 4
Self-citationDzeshka, M. S., Brown, R. A., Capodanno, D., & Lip, G. Y. H. (2016) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2016.08.007 · Cited by 5
Self-citationManagement of atrial fibrillation: easy as ABC
Mahmood, M., & Lip, G. Y. H. (2019) · Minerva Medica · doi:10.23736/s0026-4806.18.05824-x · Cited by 6
Self-citationGrymonprez, M., Steurbaut, S., Sutter, A. D., & Lahousse, L. (2020) · Open Heart · doi:10.1136/openhrt-2020-001465 · Cited by 5
“12 15–178 10 Physicians should be aware of the beneficial role of NOACs in this patient subgroup, instead of awaiting anticoagulation initiation until at least two risk factors are present.”
Harrison, S. L., Akpan, A., & Lip, G. Y. H. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17142 · Cited by 5
“The net clinical benefit of OACs compared with no treatment or aspirin is clear for most people with AF, apart from those at lowest stroke risk.(2) The common risk factors for incident AF are also risk factors for stroke and bleeding in AF.”
BackgroundSelf-citationRitchie, L. A., Harrison, S. L., Penson, P. E., Akbari, A., Torabi, F., Hollinghurst, J., Harris, D. E., Oke, O. B., Akpan, A., Halcox, J., et al. (2024) · Age and Ageing · doi:10.1093/ageing/afae021 · Cited by 4
Self-citationEditors’ Choice 2015 papers in Thrombosis and Haemostasis
Weber, C., & Lip, G. Y. H. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-11-0911 · Cited by 4
“showed positive overall advantage in terms of net clinical benefit for OAC even in patients with AF and one stroke risk factor (39).”
BackgroundSelf-citationLee, K. B., Kim, T., Park, J., Park, J., Kang, K., Kim, J., Park, H. W., Choi, E., Kim, J., Lee, Y. S., et al. (2022) · Yonsei Medical Journal · doi:10.3349/ymj.2022.63.4.317 · Cited by 4
Optimizing stroke prevention in elderly patients with atrial fibrillation
Lip, G. Y. H. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13480 · Cited by 4
Self-citationMisconceptions on Interpretation of Risk Prediction Tools in Atrial Fibrillation
Nielsen, P. B., Larsen, T. B., & Lip, G. Y. H. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.11.038 · Cited by 4
“Atrial fibrillation patients with one stroke risk factor (ie, CHA2DS2-VASc score of 1 in males or 2 in females) have a positive net clinical benefit from OAC treatment, while patients with a CHA2DS2-VASc score of 0 in males or 1 in females did not benefit from OAC or even aspirin, compared with no treatment.(4) In the…”
BackgroundSelf-citationVoukalis, C., & Lip, G. Y. H. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.02.010 · Cited by 4
Self-citationPotpara, T., & Olesen, J. B. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.076 · Cited by 4
Polymeris, A. A., Koga, M., Strbian, D., Adhiyaman, V., Krishnan, M., Branca, M., Horvath, T., Goeldlin, M. B., Shim, G. C., Gumbinger, C., et al. (2025) · Journal of Stroke · doi:10.5853/jos.2024.04322 · Cited by 3
“We additionally analyzed the net clinical benefit of antiplatelet use over non-use, adopting established methodology as in prior research, 12,13 with weighting of the type of events for their impact on death and disability relative to recurrent ischemic stroke or systemic embolism.”
InfluentialShahid, F., Shantsila, E., & Lip, G. Y. H. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw049 · Cited by 3
Self-citationStroke prevention in atrial fibrillation: can we do better?
Lane, D. A., & Lip, G. Y. H. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.117 · Cited by 3
Self-citationShahid, F., Shantsila, E., & Lip, G. Y. H. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv057 · Cited by 3
Self-citation2025 Thai guideline for the diagnosis and management of atrial fibrillation
Ngarmukos, T., Methavigul, K., Rungpradubvong, V., Apiyasawat, S., Wongcharoen, W., Pumprueg, S., Boonyapisit, W., Suwanagool, A., Chantrarat, T., Makarawate, P., et al. (2025) · Asian Biomedicine · doi:10.2478/abm-2025-0028 · Cited by 2
“Patients with an annual risk of ≥1% but 2% for ischemic stroke and thromboembolism should be considered for OAC, balancing the benefits of stroke and thromboembolism risk reduction versus the individual patient’s bleeding risk [29, 30].”
InfluentialThromboemboliás kockázat pitvarfibrillációban
Csanádi, Z. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30575 · Cited by 2
Nielsen, P. B., Potpara, T., & Lip, G. Y. H. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.07.003 · Cited by 2
Self-citationOkutucu, S. (2020) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2020.17064 · Cited by 2
“equal weight, and the paroxysmal nature of the AF may be considered (18).”
Shahid, F., Lip, G. Y. H., & Shantsila, E. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.05.002 · Cited by 1
Self-citationStroke prevention in atrial fibrillation: Where are we now?
Lip, G. Y. H. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.11.002 · Cited by 1
“The net clinical benefit is also positive for OAC vs untreated or OAC vs aspirin; in contrast, the NCB is neutral/negative for aspirin vs untreated.(15)”
Self-citationBeneficios y riesgos de los anticoagulantes orales en la fibrilación auricular
Roldána, V., & Marín, F. R. (2019) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(19)30029-9 · Cited by 1
Optimizing prognosis in atrial fibrillation: A call to action in Portugal
Ferreira, J., António, N., Cortez‐Dias, N., Gonçalves, L. R., Sargento‐Freitas, J., HAFE, P. V., & Gil, V. M. (2020) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2020.07.011 · Cited by 1
Lip, G. Y. H. (2016) · Circulation · doi:10.1161/circulationaha.116.023663 · Cited by 1
“European Society of Cardiology (ESC) guideline recommendations.(21)”
BackgroundSelf-citationMazurek, M., & Lip, G. Y. H. (2017) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616688455 · Cited by 1
Self-citationNielsen, P. B., Larsen, T. B., & Lip, G. Y. H. (2016) · Stroke · doi:10.1161/strokeaha.116.013672
Self-citationPotpara, T., Jokić, V., & Mijatovic, Z. (2016) · Srce i krvni sudovi · doi:10.5937/siks1601018p
Primärprävention und Sekundärprävention des Hirninfarkts
Ringelstein, E. B. (2020) · Springer Reference Medizin · doi:10.1007/978-3-662-60676-6_149
Risk Stratification in Atrial Fibrillation
Shahid, F., Dzeshka, M. S., Shantsila, E., & Lip, G. Y. H. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55429-9.00004-2
Self-citationNielsen, P. B., Buchan, I. E., & Lip, G. Y. H. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.038
Self-citationSchlaganfall – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung
Uphaus, T., & Gröschel, K. (2021) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-62426-5_43
Capiau, A., Grymonprez, M., Backer, T. L. M. D., Gevaert, S., Boussery, K., & Lahousse, L. (2021) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.77.21.107
Metadata
- Authors
- Skjøth, F., Nielsen, P., Larsen, T. B., & Lip, G.
- Affiliations
- Birmingham City Hospital (GB)
- Aalborg University Hospital (DK)
- Corresponding author
- Lip, Gregory
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2015
- Volume
- 114
- Issue
- 10
- Pages
- 826-834
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W2160740406
- Cited by
- 106
- References
- 30
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 9 · 2020: 7 · 2019: 9 · 2018: 11 · 2017: 15 · 2016: 39 · 2015: 4
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- non-valvular atrial fibrillation, CHA2DS2-VASc score, oral anticoagulation, warfarin, aspirin, stroke prevention, intracranial hemorrhage, bleeding risk, net clinical benefit
- MeSH terms
- Administration, Oral, Aged, Aged, 80 and over, Aspirin, Atrial Fibrillation, Decision Support Techniques, Denmark, Female, Fibrinolytic Agents, Hemorrhage, Humans, Male, Middle Aged, Predictive Value of Tests, Registries, Risk Factors, Time Factors, Warfarin, Treatment Outcome, Risk Assessment, Patient Selection, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
